EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis

Susanne Naehrig, Christina Shad, Magdalena Breuling, Melanie Goetschke, Katharina Habler iD, Sarah Sieber, Johanna Kastenberger, Alexandra Katharina Kunzelmann iD, Olaf Sommerburg iD, Uwe Liebchen iD, Juergen Behr iD, Michael Vogeser und 1 weitere

Journal of Personalized Medicine · 17.10.2024 · 14 (10) · 1065

DOI: 10.3390/jpm14101065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 17.10.2024. Verfasst von Susanne Naehrig und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Center for Adults, Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the Germ…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Zentrum für Lungenforschung, Deutsche Zentrum für Lungenforschung (DZL).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Elexacaftor, tezacaftor, and ivacaftor (ETI) have significantly improved lung function in people with cystic fibrosis (pwCF). Despite exceptional improvements in most cases, treatment-related inter-subject variability and drug–drug interactions that complicate modulator therapy have been reported.

Methods

This retrospective analysis presents data on the serum concentration of ETI in our pwCF with full or reduced dosage from August 2021 to December 2023 via routine therapeutic drug monitoring (TDM). The data were compared with the maximum drug concentrations (Cmax) from the pharmaceutical company’s summary of product characteristics.

Results

A total of 786 blood samples from 155 pwCF (41% female, 59% male) were analyzed. The examinations were divided into four groups: full dose within the given tmax (38.5% of all measurements), full dose outside the tmax (29%), reduced dose within the tmax (19.2%), and reduced dose outside the tmax (13.2%). In pwCF receiving the full dose and blood taken within the tmax, 45.3% of serum concentrations of elexacaftor, 51.1% of serum concentrations of ivacaftor, and 8.9% of serum concentrations of tezacaftor were found to be above the Cmax, respectively. For those on reduced doses within the tmax, 24.5% had a serum concentration of elexacaftor, 23.2% had a serum concentration of ivacaftor, and 2.5% had a serum concentration of tezacaftor above the Cmax, respectively.

Conclusions

Many pwCF under ETI therapy have Cmax values for elexacaftor and ivacaftor above the recommended range, even on reduced doses or before the tmax was reached. This highlights the value of a TDM program. Further pharmacokinetic studies are necessary.

Schlagwörter

Stichwörter der Autor:innen

cystic fibrosiselexacaftorivacaftorserum concentrationstezacaftortherapeutic drug monitoring

Autor:innen und Institutionen

  • Cystic Fibrosis Center for Adults, Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), 80336 Munich, Germany.
  • Institute of Laboratory Medicine, LMU University Hospital, LMU Munich, 813777 Munich, Germany.
  • STAT-UP Statistical Consulting & Data Science GmbH, 80333 Munich, Germany.
  • Department of Anesthesiology, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
  • Division of Pediatric Pulmonology, Allergy and Cystic Fibrosis Center, Department of Pediatrics, University Hospital Heidelberg, Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany.
  • Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), 81377 Munich, Germany.

ORCID-Profile: Katharina Habler, Alexandra Katharina Kunzelmann, Olaf Sommerburg, Uwe Liebchen, Juergen Behr, Michael Paal

Förderung

  • Deutsches Zentrum für Lungenforschung
  • Deutsche Zentrum für Lungenforschung (DZL)

Zitieren

APA

Naehrig, S., Shad, C., Breuling, M., Goetschke, M., Habler, K., Sieber, S., Kastenberger, J., Kunzelmann, A. K., Sommerburg, O., Liebchen, U., Behr, J., Vogeser, M., & Paal, M. (2024). Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis. Journal of Personalized Medicine, 14(10), 1065. https://doi.org/10.3390/jpm14101065

Vancouver

Naehrig S, Shad C, Breuling M, Goetschke M, Habler K, Sieber S, et al. Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis. Journal of Personalized Medicine. 2024;14(10):1065. doi:10.3390/jpm14101065

BibTeX
@article{Naehrig2024,
  author = {Naehrig, Susanne and Shad, Christina and Breuling, Magdalena and Goetschke, Melanie and Habler, Katharina and Sieber, Sarah and Kastenberger, Johanna and Kunzelmann, Alexandra Katharina and Sommerburg, Olaf and Liebchen, Uwe and Behr, Juergen and Vogeser, Michael and Paal, Michael},
  title = {Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis},
  journal = {Journal of Personalized Medicine},
  year = {2024},
  volume = {14},
  number = {10},
  pages = {1065},
  doi = {10.3390/jpm14101065}
}
Kostenlos starten →